-transparent.png){kind=logo}
Insulin-like growth factor I (IGF-I) binding sites were characterized in normal and neoplastic endometrium. The characteristics of the endometrial IGF-I receptor are similar to those reported for other tissues. The binding of 125I-IGF-I to the endometrial membranes is saturable and time, temperature, and pH dependent. The 125I-IGF-I binding activity to the membranes obtained from differentiated and undifferentiated adenocarcinoma as well as sarcoma of the endometrium was significantly higher (P less than 0.05) when compared to the binding activity of the membranes obtained from normal endometrium. The Scatchard analysis of the competitive binding data of both normal and neoplastic endometrium revealed linear plots. This indicated a single class binding site for IGF-I with equilibrium dissociation constants (Kd) of 5.0, 6.8, 6.94, and 6.88 nM for normal, differentiated, and undifferentiated adenocarcinoma, and sarcoma of the endometrium, respectively. Therefore, the differences observed in 125I-IGF-I binding between normal and neoplastic endometrial membranes was due to an increase in the number of IGF-I binding sites and not to a change in receptor binding affinity. Autoradiograms from affinity labelling studies revealed a band corresponding to Mr 132,000 subunit of the receptor which is characteristic of the type I receptor reported for other tissues. A dimer of the alpha subunit (Mr 263,000) was also observed in all four categories of endometrial tissue. Additionally, autoradiograms obtained from sarcoma of the endometrium revealed a Mr 40,000 band that was only displaced by IGF-I and IGF-II peptides but not by the monoclonal antibody alpha IR-3 to the type I receptor. These suggest that the band is representative of the IGF-I or IGF-II binding protein. A similar band was not observed in the other tissues. The results show that the human endometrium contains high affinity IGF-I or IGF-II binding sites. The fact that IGF-I binding activity was significantly higher for neoplastic endometrium suggests that IGF-I may play an important role on supporting the growth of this neoplastic tissue.
F Talavera, and
R K Reynolds, and
J A Roberts, and
K M Menon
January 1999,
International journal of cancer,
F Talavera, and
R K Reynolds, and
J A Roberts, and
K M Menon
April 1993,
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists,
F Talavera, and
R K Reynolds, and
J A Roberts, and
K M Menon
October 1985,
The Journal of clinical endocrinology and metabolism,
F Talavera, and
R K Reynolds, and
J A Roberts, and
K M Menon
January 1994,
World journal of surgery,
F Talavera, and
R K Reynolds, and
J A Roberts, and
K M Menon
February 1997,
Acta obstetricia et gynecologica Scandinavica,
F Talavera, and
R K Reynolds, and
J A Roberts, and
K M Menon
March 2005,
Clinical biochemistry,
F Talavera, and
R K Reynolds, and
J A Roberts, and
K M Menon
July 1990,
The Journal of clinical endocrinology and metabolism,
F Talavera, and
R K Reynolds, and
J A Roberts, and
K M Menon
June 1992,
Fertility and sterility,
F Talavera, and
R K Reynolds, and
J A Roberts, and
K M Menon
January 1994,
Diabete & metabolisme,
F Talavera, and
R K Reynolds, and
J A Roberts, and
K M Menon
June 1986,
The Journal of clinical endocrinology and metabolism,
